The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was $0.65 for the day, up 21.07% from the previous closing price of $0.54. In other words, the price has increased by $21.07 from its previous closing price. On the day, 0.63 million shares were traded. VRCA stock price reached its highest trading level at $0.6641 during the session, while it also had its lowest trading level at $0.51.
Ratios:
Our analysis of VRCA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.22 and its Current Ratio is at 1.34.
Needham Upgraded its Hold to Buy on July 25, 2023, while the target price for the stock was maintained at $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 26 ’24 when Hayes Christopher G. sold 26,183 shares for $2.66 per share. The transaction valued at 69,647 led to the insider holds 115,303 shares of the business.
Hayes Christopher G. sold 9,530 shares of VRCA for $23,444 on Aug 27 ’24. The CHIEF LEGAL OFFICER now owns 105,773 shares after completing the transaction at $2.46 per share. On Aug 26 ’24, another insider, Goldenberg Gary, who serves as the Chief Medical Officer of the company, sold 9,888 shares for $2.66 each. As a result, the insider received 26,302 and left with 97,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRCA now has a Market Capitalization of 59702888 and an Enterprise Value of 59312884. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48. Its current Enterprise Value per Revenue stands at 7.839 whereas that against EBITDA is -0.926.
Stock Price History:
The Beta on a monthly basis for VRCA is 1.61, which has changed by -0.86265826 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, VRCA has reached a high of $11.41, while it has fallen to a 52-week low of $0.54. The 50-Day Moving Average of the stock is -3.23%, while the 200-Day Moving Average is calculated to be -77.17%.
Shares Statistics:
VRCA traded an average of 415.85K shares per day over the past three months and 413310 shares per day over the past ten days. A total of 91.78M shares are outstanding, with a floating share count of 49.69M. Insiders hold about 45.86% of the company’s shares, while institutions hold 32.66% stake in the company. Shares short for VRCA as of 1740700800 were 2032368 with a Short Ratio of 4.89, compared to 1738281600 on 2015811. Therefore, it implies a Short% of Shares Outstanding of 2032368 and a Short% of Float of 3.04.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Verrica Pharmaceuticals Inc (VRCA) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.31 and -$0.5 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.34, with 4.0 analysts recommending between -$0.14 and -$0.7.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $4.4M to a low estimate of $1M. As of the current estimate, Verrica Pharmaceuticals Inc’s year-ago sales were $3.83MFor the next quarter, 5 analysts are estimating revenue of $3.67M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $1.82M.
A total of 6 analysts have provided revenue estimates for VRCA’s current fiscal year. The highest revenue estimate was $25M, while the lowest revenue estimate was $7.68M, resulting in an average revenue estimate of $16.85M. In the same quarter a year ago, actual revenue was $7.57MBased on 5 analysts’ estimates, the company’s revenue will be $33.2M in the next fiscal year. The high estimate is $50M and the low estimate is $24.16M.
